-
EP3319965
European procedure
Extract from the Register of European Patents
EP About this file: EP3319965
| EP3319965 - NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 10.03.2023 Database last updated on 31.08.2024 | |
| Former | The patent has been granted Status updated on 02.04.2022 | ||
| Former | Grant of patent is intended Status updated on 19.11.2021 | ||
| Former | Examination is in progress Status updated on 17.09.2021 | ||
| Former | Grant of patent is intended Status updated on 17.05.2021 | ||
| Former | Examination is in progress Status updated on 28.05.2019 | ||
| Former | Request for examination was made Status updated on 13.04.2018 | ||
| Former | The international publication has been made Status updated on 13.01.2017 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Biomedical Research Foundation of the Academy of Athens 4 Soranou Efessiou 11527 Athens / GR | [2018/20] | Inventor(s) | 01 /
STELLAS, Dimitris 12 Anavritis St. 11143 Athens / GR | 02 /
TAMVAKOPOULOS, Constantin 4 Ilektras St. Kifissia 14562 Athens / GR | 03 /
KLINAKIS, Apostolos 5 Ellis Alexiou St. Agia Marina 71410 Iraklio / GR | 04 /
EFSTRATIADIS, Argiris 37-39 Kleomenous St. 10676 Athens / GR | 05 /
COURNIA, Zoe 8B Nileos St. 14564 Kifissia / GR | [2018/20] | Representative(s) | Eder, Michael df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte PartG mbB Theatinerstrasse 16 80333 München / DE | [2018/20] | Application number, filing date | 16736480.1 | 08.07.2016 | [2018/20] | WO2016EP66340 | Priority number, date | EP20150175918 | 08.07.2015 Original published format: EP 15175918 | [2018/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017005919 | Date: | 12.01.2017 | Language: | EN | [2017/02] | Type: | A1 Application with search report | No.: | EP3319965 | Date: | 16.05.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.01.2017 takes the place of the publication of the European patent application. | [2018/20] | Type: | B1 Patent specification | No.: | EP3319965 | Date: | 04.05.2022 | Language: | EN | [2022/18] | Search report(s) | International search report - published on: | EP | 12.01.2017 | Classification | IPC: | A61K31/196, A61K31/337, C07D487/04, A61K31/365, A61K31/415, A61K31/4196, A61K31/444, A61K31/517, A61K31/519, A61K31/566, A61K31/58, A61K31/635, A61K31/704, A61K31/7068, A61P35/02 | [2021/11] | CPC: |
C07D487/04 (EP,US);
A61K31/415 (EP,US);
A61K31/4196 (EP,US);
A61K31/519 (EP,US);
A61K31/58 (EP,US);
A61K31/635 (EP,US);
A61K31/7068 (EP,US);
A61P35/02 (EP,US);
C07B43/06 (US);
A61K2300/00 (US);
A61K31/196 (EP,US);
A61K31/337 (EP,US);
A61K31/365 (EP,US);
A61K31/444 (EP,US);
A61K31/517 (EP,US);
| C-Set: |
A61K31/415, A61K2300/00 (EP,US);
A61K31/4196, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US);
A61K31/58, A61K2300/00 (US,EP); |
| Former IPC [2018/20] | C07D487/04, A61P35/00, A61K31/51 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/20] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | NEUE VERBINDUNGEN ZUR BEHANDLUNG ODER PRÄVENTION VON KREBSERKRANKUNGEN | [2021/20] | English: | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | [2018/20] | French: | NOUVEAUX COMPOSÉS UTILISABLES DANS LE TRAITEMENT OU LA PRÉVENTION DE MALADIES CANCÉREUSES | [2018/20] |
| Former [2018/20] | NEUARTIGE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG ODER VORBEUGUNG VON KREBSERKRANKUNGEN | Entry into regional phase | 05.01.2018 | National basic fee paid | 05.01.2018 | Designation fee(s) paid | 05.01.2018 | Examination fee paid | Examination procedure | 05.01.2018 | Examination requested [2018/20] | 05.01.2018 | Date on which the examining division has become responsible | 16.08.2018 | Amendment by applicant (claims and/or description) | 03.06.2019 | Despatch of a communication from the examining division (Time limit: M07) | 03.01.2020 | Reply to a communication from the examining division | 30.06.2020 | Despatch of a communication from the examining division (Time limit: M04) | 10.11.2020 | Reply to a communication from the examining division | 18.05.2021 | Communication of intention to grant the patent | 15.09.2021 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 15.09.2021 | Fee for grant paid | 15.09.2021 | Fee for publishing/printing paid | 26.11.2021 | Communication of intention to grant the patent | 28.03.2022 | Receipt of the translation of the claim(s) | Opposition(s) | 07.02.2023 | No opposition filed within time limit [2023/15] | Fees paid | Renewal fee | 30.07.2018 | Renewal fee patent year 03 | 22.07.2019 | Renewal fee patent year 04 | 21.08.2020 | Renewal fee patent year 05 | 28.07.2021 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 08.07.2016 | AL | 04.05.2022 | AT | 04.05.2022 | CY | 04.05.2022 | CZ | 04.05.2022 | DK | 04.05.2022 | EE | 04.05.2022 | ES | 04.05.2022 | FI | 04.05.2022 | HR | 04.05.2022 | IT | 04.05.2022 | LT | 04.05.2022 | LV | 04.05.2022 | MC | 04.05.2022 | MK | 04.05.2022 | NL | 04.05.2022 | PL | 04.05.2022 | RO | 04.05.2022 | RS | 04.05.2022 | SE | 04.05.2022 | SI | 04.05.2022 | SK | 04.05.2022 | SM | 04.05.2022 | TR | 04.05.2022 | IE | 08.07.2022 | LU | 08.07.2022 | BE | 31.07.2022 | CH | 31.07.2022 | FR | 31.07.2022 | LI | 31.07.2022 | BG | 04.08.2022 | GB | 04.08.2022 | NO | 04.08.2022 | GR | 05.08.2022 | IS | 04.09.2022 | PT | 05.09.2022 | DE | 01.02.2023 | [2024/29] |
| Former [2024/22] | HU | 08.07.2016 | |
| AL | 04.05.2022 | ||
| AT | 04.05.2022 | ||
| CY | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| IT | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| MK | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| GB | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2024/20] | HU | 08.07.2016 | |
| AL | 04.05.2022 | ||
| AT | 04.05.2022 | ||
| CY | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| IT | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| GB | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2024/18] | HU | 08.07.2016 | |
| AL | 04.05.2022 | ||
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| IT | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| GB | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2024/11] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| IT | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| GB | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2023/47] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| GB | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2023/33] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| IE | 08.07.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2023/25] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SI | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| LU | 08.07.2022 | ||
| BE | 31.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2023/23] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| LU | 08.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| DE | 01.02.2023 | ||
| Former [2023/22] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| LU | 08.07.2022 | ||
| CH | 31.07.2022 | ||
| FR | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2023/21] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| LU | 08.07.2022 | ||
| CH | 31.07.2022 | ||
| LI | 31.07.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2023/17] | AL | 04.05.2022 | |
| AT | 04.05.2022 | ||
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2023/11] | AT | 04.05.2022 | |
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| MC | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2023/09] | AT | 04.05.2022 | |
| CZ | 04.05.2022 | ||
| DK | 04.05.2022 | ||
| EE | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RO | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| SK | 04.05.2022 | ||
| SM | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2023/07] | AT | 04.05.2022 | |
| DK | 04.05.2022 | ||
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2022/51] | AT | 04.05.2022 | |
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| IS | 04.09.2022 | ||
| PT | 05.09.2022 | ||
| Former [2022/50] | AT | 04.05.2022 | |
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| PL | 04.05.2022 | ||
| RS | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| PT | 05.09.2022 | ||
| Former [2022/49] | AT | 04.05.2022 | |
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| HR | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| LV | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| BG | 04.08.2022 | ||
| NO | 04.08.2022 | ||
| GR | 05.08.2022 | ||
| PT | 05.09.2022 | ||
| Former [2022/48] | AT | 04.05.2022 | |
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| NL | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| NO | 04.08.2022 | ||
| PT | 05.09.2022 | ||
| Former [2022/47] | AT | 04.05.2022 | |
| ES | 04.05.2022 | ||
| FI | 04.05.2022 | ||
| LT | 04.05.2022 | ||
| SE | 04.05.2022 | ||
| NO | 04.08.2022 | ||
| PT | 05.09.2022 | Cited in | International search | [YD] - ANKE KIESSLING ET AL, "Selective Inhibition of c-Myc/Max Dimerization by a Pyrazolo[1,5-a]pyrimidine", CHEMMEDCHEM, (20070514), vol. 2, no. 5, doi:10.1002/cmdc.200600294, ISSN 1860-7179, pages 627 - 630, XP055118564 [YD] 1-15 * the whole document * DOI: http://dx.doi.org/10.1002/cmdc.200600294 | [Y] - JEREMY L. YAP ET AL, "Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions", MEDCHEMCOMM, United Kingdom, (20120101), vol. 3, no. 5, doi:10.1039/c2md00289b, ISSN 2040-2503, page 541, XP055299857 [Y] 1-15 * figure 4 * DOI: http://dx.doi.org/10.1039/c2md00289b | by applicant | - MCGRATH J.P., NATURE, (1983), vol. 304, pages 501 - 506 | - WATSON J., OPEN BIOL, (2013), vol. 3, page 120144 | - VITA, M.; HENRIKSSON, M., SEMIN CANCER BIOL, (2006), vol. 16, pages 318 - 330 | - XU Y., BIOORG MED CHEM, (2006), vol. 14, pages 2660 - 2673 | - YAMADA H ET AL., JPN J CANCER RES., (1986), vol. 77, pages 370 - 375 | - SOUCEK, L. ET AL., NATURE, (2008), vol. 455, pages 679 - 683 | - D'AGNANO, I. ET AL., J CELL PHYSIOL, (2007), vol. 210, pages 72 - 80 | - BERG, T. ET AL., PROC NATL ACAD SCI U S A, (2002), vol. 99, pages 3830 - 3835 | - YIN X., ONCOGENE, (2003), vol. 22, pages 6151 - 6159 | - XU Y. ET AL., BIOORG MED CHEM, (2006), vol. 14, pages 2660 - 2673 | - KIESSLING, A. ET AL., CHEMMEDCHEM, (2007), vol. 2, pages 627 - 630 | - GOMEZ-CURET ET AL., J PEDIATR SURG, (2006), vol. 41, pages 207 - 211 | - HUANG ET AL., EXP HEMATOL, (2006), vol. 34, pages 1480 - 1489 | - LIN ET AL., ANTICANCER DRUGS, (2007), vol. 18, pages 161 - 70 | - SAMPSON ET AL., CANCER RES, (2007), vol. 67, pages 9762 - 70 | - GUO ET AL., CANCER CHEMOTHER PHARMACOL, (2009), vol. 63, pages 615 - 625 | - ALBORAN, I.M. ET AL., "Analysis of C-MYC function in normal cells via conditional gene-targeted mutation", IMMUNITY, (2001), vol. 14, pages 45 - 55 | - BERG, T. ET AL., "Small-molecule antagonists of Myc Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts", PROC NATL ACAD SCI U S A, (2002), vol. 99, doi:doi:10.1073/pnas.062036999, pages 3830 - 3835, XP002995347 DOI: http://dx.doi.org/10.1073/pnas.062036999 | - D'AGNANO, I. ET AL., "Oligopeptides Impairing the Myc-Max Heterodimerization Inhibit Lung Cancer Cell Proliferation by Reducing Myc Transcriptional Activity", J CELL PHYSIOL, (2007), vol. 210, pages 72 - 80 | - GOMEZ-CURET, I. ET AL., "c-Myc inhibition negatively impacts lymphoma growth", J PEDIATR SURG, (2006), vol. 41, doi:doi:10.1016/j.jpedsurg.2005.10.025, pages 207 - 211, XP005235919 DOI: http://dx.doi.org/10.1016/j.jpedsurg.2005.10.025 | - GUO, J. ET AL., "Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice", CANCER CHEMOTHER PHARMACOL, (2009), vol. 63, pages 615 - 625, XP019708041 | - HUANGA, MJ., "A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia", EXP HEMATOL, (2006), vol. 34, pages 1480 - 1489 | - KIESSLING, A. ET AL., "Selective Inhibition of c-Myc/Max Dimerization by a PyrazoloA[1,5-a]-pyrimidine", CHEM MED CHEM, (2007), vol. 2, doi:doi:10.1002/cmdc.200600294, pages 627 - 630, XP055118564 DOI: http://dx.doi.org/10.1002/cmdc.200600294 | - LIN CP ET AL., "Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells", ANTICANCER DRUGS, (2007), vol. 18, pages 161 - 70 | - MCGRATH J.P. ET AL., "Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene", NATURE, (1983), vol. 304, pages 501 - 506 | - MATEYAK MK; OBAYA AJ; ADACHI S; SEDIVY JM, "Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination", CELL GROWTH DIFFER, (1997), vol. 8, no. 10, pages 1039 - 1048 | - MOSMANN, T., "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays", J IMMUNOL METHODS, (1983), vol. 65, doi:doi:10.1016/0022-1759(83)90303-4, pages 55 - 63, XP023973702 DOI: http://dx.doi.org/10.1016/0022-1759(83)90303-4 | - SAMPSON VB ET AL., "MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells", CANCER RES, (2007), vol. 67, doi:doi:10.1158/0008-5472.CAN-07-2462, pages 9762 - 70, XP055157493 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-07-2462 | - SOUCEK, L. ET AL., "Modelling Myc inhibition as a cancer therapy", NATURE, (2008), vol. 455, doi:doi:10.1038/nature07260, pages 679 - 683, XP055122479 DOI: http://dx.doi.org/10.1038/nature07260 | - STELLAS D. ET AL., "Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer", J. NATL CANCER INST, (2014), vol. 106 | - STEWART, T. A.; PATTENGALE, P. K.; LEDER, P., "Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes", CELL, (1984), vol. 38, doi:doi:10.1016/0092-8674(84)90257-5, pages 627 - 637, XP023910866 DOI: http://dx.doi.org/10.1016/0092-8674(84)90257-5 | - VITA, M.; HENRIKSSON, M., "The Myc oncoprotein as a therapeutic target for human cancer", SEMIN CANCER BIOL, (2006), vol. 16, doi:doi:10.1016/j.semcancer.2006.07.015, pages 318 - 330, XP024908049 DOI: http://dx.doi.org/10.1016/j.semcancer.2006.07.015 | - WATSON J, "Oxidants, antioxidants and the current incurability of metastatic cancers", OPEN BIOL, (2013), vol. 3, page 120144 | - XU Y. ET AL., "A credit-card library approach for disrupting protein-protein interactions", BIOORG MED CHEM, (2006), vol. 14, doi:doi:10.1016/j.bmc.2005.11.052, pages 2660 - 2673, XP025133157 DOI: http://dx.doi.org/10.1016/j.bmc.2005.11.052 | - YAMADA H ET AL., "Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes", JPN J CANCER RES., (1986), vol. 77, pages 370 - 375 | - YIN X., "Low molecular weight inhibitors of Myc-Max interaction and function", ONCOGENE, (2003), vol. 22, doi:doi:10.1038/sj.onc.1206641, pages 6151 - 6159, XP002995346 DOI: http://dx.doi.org/10.1038/sj.onc.1206641 |